|1.||Coles, Alasdair J: 21 articles (12/2014 - 01/2006)|
|2.||Mackinnon, Stephen: 19 articles (01/2015 - 02/2002)|
|3.||Hale, Geoff: 17 articles (03/2015 - 02/2002)|
|4.||Osterborg, Anders: 14 articles (11/2011 - 01/2002)|
|5.||Keating, Michael J: 14 articles (08/2011 - 05/2002)|
|6.||Pagliuca, Antonio: 13 articles (03/2015 - 09/2002)|
|7.||Mufti, Ghulam J: 13 articles (07/2014 - 09/2002)|
|8.||Hallek, Michael: 13 articles (08/2013 - 01/2002)|
|9.||Faderl, Stefan: 13 articles (06/2013 - 08/2003)|
|10.||O'Brien, Susan: 13 articles (08/2011 - 01/2004)|
|1.||B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
03/01/2012 - "Alemtuzumab has been shown to be effective in poor-prognosis chronic lymphocytic leukemia (CLL); treatment, however, has been associated with significant toxicity. "
06/01/2007 - "With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (cll)?What toxicities are associated with the use of alemtuzumab?Which"
06/01/2009 - "Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics Alemtuzumab is effective in B-cell chronic lymphocytic leukemia (CLL) with 17p deletion, which responds poorly to chemotherapeutic agents. "
01/15/2005 - "The anti-CD52 antibody alemtuzumab is effective in the treatment of patients with chronic lymphocytic leukemia (CLL). "
03/15/2004 - "Alemtuzumab therapy is effective for some refractory chronic lymphocytic leukemia (CLL), but identifying responders requires at least 8 weeks of therapy. "
|2.||Relapsing-Remitting Multiple Sclerosis
07/01/2009 - "Phase II clinical trials revealed that the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath-1H) is highly effective in the treatment of early relapsing-remitting multiple sclerosis. "
01/01/2010 - "Treatment with alemtuzumab is highly effective in relapsing-remitting multiple sclerosis; however, 30% of patients develop autoimmunity. "
11/24/2012 - "For patients with first-line treatment-refractory relapsing-remitting multiple sclerosis, alemtuzumab could be used to reduce relapse rates and sustained accumulation of disability. "
01/01/2015 - "Alemtuzumab, a humanized monoclonal antibody against CD52, is effective in the treatment of early relapsing-remitting multiple sclerosis (MS). "
03/01/2014 - "Alemtuzumab is an effective treatment for patients with relapsing-remitting multiple sclerosis, and has a generally acceptable tolerability profile. "
|3.||Graft vs Host Disease (Graft-Versus-Host Disease)
07/01/2012 - "Factors predicting OS (P value by log rank <0·05) were: comorbidity index <3, FISH rank (Dohner) and 17p deletion, alemtuzumab pre-HSCT, achievement of CR post-HSCT, donor chimerism >90%, clearance of FISH abnormality post-HSCT and absence of high-grade (3-4) graft-versus-host disease. "
01/01/2014 - "The incidence of de novo chronic graft-versus-host disease (GVHD) was low at 19%, illustrating the efficacy of alemtuzumab for GVHD prophylaxis. "
05/01/2013 - "Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease."
05/01/2009 - "Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study."
10/01/2015 - "The incidence of severe acute graft-versus-host disease tended to be higher after the lower alemtuzumab dose (17% versus 4%; P = .15). "
08/01/2012 - "Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). "
01/01/2015 - "In clinical trials, alemtuzumab has shown impressive efficacy with regard to clinical and radiological outcomes in relapsing multiple sclerosis, along with sustained long-term beneficial effects, and it is attractive for its once-yearly administration. "
10/23/2008 - "Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis. "
01/01/2015 - "Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis."
04/01/2009 - "[Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis]."
02/01/2006 - "Alemtuzumab (Campath-1H)-based conditioning regimens are effective in preventing GVHD, but are associated with very high rates of cytomegalovirus (CMV) infection, a major limitation to their use. "
08/01/2005 - "Low-dose alemtuzumab induced significant responses in these patients (16% complete remission, 25% partial remission), with mild hematologic and extrahematologic side effects and a low rate of infections, even in the presence of long-lasting severe immunosuppression."
11/01/2007 - "We report a case of Sézary syndrome treated successfully with alemtuzumab but who died of treatment-related infection."
04/01/2003 - "Thus elimination of late mortalities related to chronic GVHD and a rapid immune reconstitution, limiting either infection or relapse related deaths, contributed to an improved outcome following T-cell depletion with Campath-1H "in the bag"."
10/10/2010 - "Alemtuzumab consolidation improved CR and MRD-negative rates after FR induction but caused serious infections in patients who had already achieved CR after induction and did not improve 2-year PFS or survival."
|7.||interferon beta 1a
|1.||Drug Therapy (Chemotherapy)
|2.||Stem Cell Transplantation
|4.||Transplantation (Transplant Recipients)
|5.||Hematopoietic Stem Cell Transplantation